Ajla Hrle
Chief Business Officer DISCO Pharmaceuticals
Ajla Hrle, Chief Business Officer at DISCO Pharmaceuticals, brings over a decade of experience in building transformative Life Science companies, driven by the mission to positively impact patient lives. She is a recognized leader in the biotechnology sector, combining her expertise as a scientist, business professional, and board member. From 2023 to 2024, Ajla served as Head of Life Sciences at ATHOS KG, the Strüngmann Family Office. Between 2016 and 2022, she held roles at Immatics N.V., most recently as Vice President of Strategic Alliances. During this time, she completed multiple licensing transactions from early-stage to commercial, contributed to public listings, led fund and direct investments, and established Corporate Communications and Alliance Management departments. Earlier, she led technical sales in Scandinavian markets at NanoTemper Technologies GmbH. Ajla obtained her PhD from the Max Planck Institute of Biochemistry and Ludwig-Maximilians-University in Munich as a Schering Foundation Fellow.
Seminars
- Integrating pan-cancer or broadly applicable targets while maintaining specificity, and using this to evidence a scalable, differentiated discovery engine without compromising safety
- How do we determine which targets align with a given modality’s safety, selectivity and therapeutic potential?
- Sharing experience demonstrating the validation of a credible platform, including evolution from platform narrative to an asset-led story
- Discussing types of deals possible for platforms versus assets, and what is the minimum evidence needed for a deal?
